These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25506455)

  • 1. A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: can causality assessment scales be utilized to identify the offending drug?
    Lim R; Choudry H; Conner K; Karnsakul W
    Case Rep Pediatr; 2014; 2014():156389. PubMed ID: 25506455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on Drug-induced Liver Injury.
    Devarbhavi H
    J Clin Exp Hepatol; 2012 Sep; 2(3):247-59. PubMed ID: 25755441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale.
    Hanatani T; Sai K; Tohkin M; Segawa K; Kimura M; Hori K; Kawakami J; Saito Y
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):984-8. PubMed ID: 24596340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.
    Das S; Behera SK; Xavier AS; Velupula S; Dkhar SA; Selvarajan S
    Clin Drug Investig; 2018 Mar; 38(3):211-218. PubMed ID: 29185238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?
    Danan G; Teschke R
    Drug Saf; 2018 Aug; 41(8):735-743. PubMed ID: 29502198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causality assessment methods in drug induced liver injury: strengths and weaknesses.
    García-Cortés M; Stephens C; Lucena MI; Fernández-Castañer A; Andrade RJ
    J Hepatol; 2011 Sep; 55(3):683-691. PubMed ID: 21349301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
    Danan G; Teschke R
    Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods.
    Teschke R; Frenzel C; Schulze J; Eickhoff A
    World J Gastroenterol; 2013 May; 19(19):2864-82. PubMed ID: 23704820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two clinical scales for causality assessment in hepatotoxicity.
    Lucena MI; Camargo R; Andrade RJ; Perez-Sanchez CJ; Sanchez De La Cuesta F
    Hepatology; 2001 Jan; 33(1):123-30. PubMed ID: 11124828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity.
    Miljkovic MM; Dobric S; Dragojevic-Simic V
    J Clin Pharm Ther; 2012 Apr; 37(2):196-203. PubMed ID: 21718339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
    Rochon J; Protiva P; Seeff LB; Fontana RJ; Liangpunsakul S; Watkins PB; Davern T; McHutchison JG;
    Hepatology; 2008 Oct; 48(4):1175-83. PubMed ID: 18798340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced Liver Injury Caused by Phenprobamate: Strong Probability Due to Repeated Toxicity.
    Duzenli T; Tanoglu A; Akyol T; Kara M; Yazgan Y
    Euroasian J Hepatogastroenterol; 2019; 9(1):49-51. PubMed ID: 31988867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Hepatotoxicity: Causality Assessment.
    Caines A; Moonka D
    Clin Liver Dis; 2020 Feb; 24(1):25-35. PubMed ID: 31753248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.
    Lewis JH; Larrey D; Olsson R; Lee WM; Frison L; Keisu M
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):327-39. PubMed ID: 18793587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiosyncratic drug hepatotoxicity: a 2008 update.
    Andrade RJ; López-Ortega S; López-Vega MC; Robles M; Cueto I; Lucena MI
    Expert Rev Clin Pharmacol; 2008 Mar; 1(2):261-76. PubMed ID: 24422651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.
    García-Cortés M; Lucena MI; Pachkoria K; Borraz Y; Hidalgo R; Andrade RJ;
    Aliment Pharmacol Ther; 2008 May; 27(9):780-9. PubMed ID: 18284654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine-Induced Liver Injury With Probable Causality as Assessed Using the Roussel Uclaf Causality Assessment Method (RUCAM).
    Shumar J; Ordway S; Junga Z; Sadowski B; Torres D
    ACG Case Rep J; 2019 Aug; 6(8):e00184. PubMed ID: 31737715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
    Teschke R
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Carbamazepine-induced Severe Cholestatic Hepatitis: Case Report and Review of Literature.
    Ganesh S; Shukla L; Kandasamy A; Benegal V
    Indian J Psychol Med; 2017; 39(5):688-690. PubMed ID: 29200572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection.
    Carrascosa MF; Lucena MI; Andrade RJ; Caviedes JR; Lavín AC; Mones JC; Rivero AP; Serrano VB
    Clin Ther; 2009 May; 31(5):1014-9. PubMed ID: 19539102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.